The Swedish Medical Products Agency has authorised the emergency use of Eli Lilly's bamlanivimab in COVID-19 patients with underlying conditions that make them more vulnerable to the virus, as reported Xinhua on Thursday.
The drug is currently under review by the European Medicines Agency.
"It is in the approval process and as the results look promising, we believe that we can take advantage of this drug in a controlled way," said Charlotta Bergquist, group manager of efficacy and safety at the Swedish Medical Products Agency.
"Treatment should be started early in the course of the disease for those who risk becoming seriously ill," she added.
To read more NewsPoints articles, click here.